+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A comparative study of the population pharmacokinetics of gentamicin and amikacin in newborn patients



A comparative study of the population pharmacokinetics of gentamicin and amikacin in newborn patients



Journal Of Clinical Pharmacy & Therapeutics. 18(6): 411-413



The population kinetics of gentamicin and amikacin were studied comparatively in newborn patients with a similar range of gestation age (37.9 +- 2.9 and 36.7 +- 3.6 weeks), postnatal age (13.8 +- 7.4 and 16.7 +- 7 days) and weight (2.85 +- 0.57 and 2.72 +- 0.75 kg), undergoing routine therapeutic monitoring of their serum levels. Individual kinetic analysis of serum drug levels was done using a single-compartment model. The population model employed assumes the existence of residual variability in the serum concentrations and interindividual variability in the pharmacokinetic parameters. The clearance and the apparent distribution volume were calculated for each patient using a two-stage method. Statistically significant differences were obtained in the distribution parameters (0.54 +- 0.17 and 0.43 +- 0.13 l/kg) of both drugs (P lt 0.05), but not in serum clearance. The interindividual variability in the pharmacokinetic parameters was similar. These results help to improve the forecasting quality of the 'a priori' methods for the initial dosing of aminoglycoside antibiotics in this type of patient.

(PDF emailed within 0-6 h: $19.90)

Accession: 008030021

Download citation: RISBibTeXText

DOI: 10.1111/j.1365-2710.1993.tb00879.x


Related references

Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrobial Agents and ChemoTherapy 19(1): 147-152, 1981

Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin. European Journal of Clinical Pharmacology 24(5): 639-642, 1983

Comparative pharmacokinetics of gentamicin, neomycin and oxytetracycline in newborn calves. Journal of Veterinary Pharmacology and Therapeutics 10(1): 54-63, 1987

Gentamicin and amikacin nephrotoxicity: comparative study in patients with initially normal renal function. Revista Medica de Chile 117(1): 10-17, 1989

Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. American Journal of Medicine 80(6b): 98-104, 1986

A comparison of the pharmacokinetics of amikacin and gentamicin. Journal of Antimicrobial ChemoTherapy 8 Suppl A: 45-49, 1981

Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. Journal of Infectious Diseases 134 Suppl: S200-S205, 1976

Comparison of amikacin and gentamicin pharmacokinetics in the critically ill. American Review of Respiratory Disease 137(4 PART 2): 472, 1988

A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Fundamental and Clinical Pharmacology 23(4): 515-520, 2009

Population pharmacokinetics of amikacin once a day in critically ill patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 34(0): 37, 1994

Population pharmacokinetics of amikacin in critically ill patients. Antimicrobial Agents and ChemoTherapy 40(7): 1682-1689, 1996

Microbiology and pharmacokinetics of gentamicin, sisomicin, netilmicin and amikacin. Advances in Clinical Pharmacology 15: 23-34, 1978

Amikacin population pharmacokinetics among paediatric burn patients. Burns 40(2): 311-318, 2014

Amikacin population pharmacokinetics in critically ill Kuwaiti patients. Biomed Research International 2013: 202818, 2013

Population pharmacokinetics of amikacin in patients with haematological malignancies. Journal of Antimicrobial ChemoTherapy 44(2): 235-242, 1999